These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12668020)

  • 1. Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitors.
    Tomczuk B; Lu T; Soll RM; Fedde C; Wang A; Murphy L; Crysler C; Dasgupta M; Eisennagel S; Spurlino J; Bone R
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1495-8. PubMed ID: 12668020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amidinohydrazones as guanidine bioisosteres: application to a new class of potent, selective and orally bioavailable, non-amide-based small-molecule thrombin inhibitors.
    Soll RM; Lu T; Tomczuk B; Illig CR; Fedde C; Eisennagel S; Bone R; Murphy L; Spurlino J; Salemme FR
    Bioorg Med Chem Lett; 2000 Jan; 10(1):1-4. PubMed ID: 10636229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis.
    Lu T; Markotan T; Coppo F; Tomczuk B; Crysler C; Eisennagel S; Spurlino J; Gremminger L; Soll RM; Giardino EC; Bone R
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3727-31. PubMed ID: 15203151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzylamine-based selective and orally bioavailable inhibitors of thrombin.
    Lee K; Jung WH; Park CW; Hong CY; Kim IC; Kim S; Oh YS; Kwon OH; Lee SH; Park HD; Kim SW; Lee YH; Yoo YJ
    Bioorg Med Chem Lett; 1998 Sep; 8(18):2563-8. PubMed ID: 9873581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocharged inhibitors of mast cell tryptase derived from potent and selective dibasic inhibitors.
    Dener JM; Wang VR; Rice KD; Gangloff AR; Kuo EY; Newcomb WS; Putnam D; Wong M
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2325-30. PubMed ID: 11527724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors.
    Rewinkel JB; Lucas H; Smit MJ; Noach AB; van Dinther TG; Rood AM; Jenneboer AJ; van Boeckel CA
    Bioorg Med Chem Lett; 1999 Oct; 9(19):2837-42. PubMed ID: 10522702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics.
    Adang AE; de Man AP; Vogel GM; Grootenhuis PD; Smit MJ; Peters CA; Visser A; Rewinkel JB; van Dinther T; Lucas H; Kelder J; van Aelst S; Meuleman DG; van Boeckel CA
    J Med Chem; 2002 Sep; 45(20):4419-32. PubMed ID: 12238922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of potential prodrugs of RWJ-445167, an oxyguanidine-based dual inhibitor of thrombin and factor Xa.
    Maryanoff BE; McComsey DF; Costanzo MJ; Yabut SC; Lu T; Player MR; Giardino EC; Damiano BP
    Chem Biol Drug Des; 2006 Jul; 68(1):29-36. PubMed ID: 16923023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary structure peptide mimetics: design, synthesis, and evaluation of beta-strand mimetic thrombin inhibitors.
    Boatman PD; Ogbu CO; Eguchi M; Kim HO; Nakanishi H; Cao B; Shea JP; Kahn M
    J Med Chem; 1999 Apr; 42(8):1367-75. PubMed ID: 10212122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of betaII tryptase.
    Levell J; Astles P; Eastwood P; Cairns J; Houille O; Aldous S; Merriman G; Whiteley B; Pribish J; Czekaj M; Liang G; Maignan S; Guilloteau JP; Dupuy A; Davidson J; Harrison T; Morley A; Watson S; Fenton G; McCarthy C; Romano J; Mathew R; Engers D; Gardyan M; Sides K; Kwong J; Tsay J; Rebello S; Shen L; Wang J; Luo Y; Giardino O; Lim HK; Smith K; Pauls H
    Bioorg Med Chem; 2005 Apr; 13(8):2859-72. PubMed ID: 15781396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of benzothiazole guanidines as novel inhibitors of thrombin and trypsin IV.
    Karle M; Knecht W; Xue Y
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4839-43. PubMed ID: 22726924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor.
    Oh YS; Yun M; Hwang SY; Hong S; Shin Y; Lee K; Yoon KH; Yoo YJ; Kim DS; Lee SH; Lee YH; Park HD; Lee CH; Lee SK; Kim S
    Bioorg Med Chem Lett; 1998 Mar; 8(6):631-4. PubMed ID: 9871573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective bicyclic lactam inhibitors of thrombin: Part 2: P1 modifications.
    Plummer JS; Berryman KA; Cai C; Cody WL; DiMaio J; Doherty AM; Edmunds JJ; He JX; Holland DR; Levesque S; Kent DR; Narasimhan LS; Rubin JR; Rapundalo ST; Siddiqui MA; Susser AJ; St-Denis Y; Winocour PD
    Bioorg Med Chem Lett; 1998 Dec; 8(23):3409-14. PubMed ID: 9873743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.
    Costanzo MJ; Maryanoff BE; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Kauffman JA; Lewis JM; Krishnan R; Tulinsky A
    J Med Chem; 1996 Aug; 39(16):3039-43. PubMed ID: 8759623
    [No Abstract]   [Full Text] [Related]  

  • 15. Macrocyclic Prodrugs of a Selective Nonpeptidic Direct Thrombin Inhibitor Display High Permeability, Efficient Bioconversion but Low Bioavailability.
    Andersson V; Bergström F; Brånalt J; Grönberg G; Gustafsson D; Karlsson S; Polla M; Bergman J; Kihlberg J
    J Med Chem; 2016 Jul; 59(14):6658-70. PubMed ID: 27347787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
    Lu T; Markotan T; Ballentine SK; Giardino EC; Spurlino J; Crysler CS; Brown K; Maryanoff BE; Tomczuk BE; Damiano BP; Shukla U; End D; Andrade-Gordon P; Bone RF; Player MR
    J Med Chem; 2010 Feb; 53(4):1843-56. PubMed ID: 20102150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [On inhibition of the coagulation enzyme thrombin by benzamidine derivatives].
    Markwardt F; Walsmann P
    Experientia; 1968 Jan; 24(1):25-6. PubMed ID: 5637604
    [No Abstract]   [Full Text] [Related]  

  • 18. Protease inhibitors. Part 2. Weakly basic thrombin inhibitors incorporating sulfonyl-aminoguanidine moieties as S1 anchoring groups: synthesis and structure-activity correlations.
    Clare BW; Scozzafava A; Briganti F; Iorga B; Supuran CT
    J Enzyme Inhib; 2000; 15(3):235-64. PubMed ID: 10811030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
    Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
    J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.
    Feng DM; Gardell SJ; Lewis SD; Bock MG; Chen Z; Freidinger RM; Naylor-Olsen AM; Ramjit HG; Woltmann R; Baskin EP; Lynch JJ; Lucas R; Shafer JA; Dancheck KB; Chen IW; Mao SS; Krueger JA; Hare TR; Mulichak AM; Vacca JP
    J Med Chem; 1997 Nov; 40(23):3726-33. PubMed ID: 9371237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.